Recruiting

Observational Study

Sponsor:

University of British Columbia

Code:

NCT04510623

Conditions

COVID-19

SARS-CoV2

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ARBs and/or ACE inhibitors

Usual Care

Study Details

Brief summary:

The coronavirus (COVID-19) pandemic continues to grow exponentially. Angiotensin II levels are increased in human influenza and are associated with influenza viral load, disease progression and mortality. Preliminary data shows angiotensin II receptor blockers (ARBs) limits lung injury in murine influenza H7N9, as well as viral titre and RNA. ARBs could limit viral titre and organ injury in COVID-19. We will therefore collect clinical chart data and test angiotensin II levels of patients who are admitted to ICU with COVID-19 to determine whether there is a correlation between taking ARBs and clinical outcomes in these patients.

Other blood biomarkers and clinical risk factors for COVID-19 have come to light in recent weeks. We include these in our observational analysis to help generate an understanding of COVID-19 presentation and blood biomarker characterization of disease.

Conditions

COVID-19

SARS-CoV2

Study ID

NCT04510623

Start date

Mar 17, 2020

Status verified date

Aug, 2020

Completion date

Jun 30, 2022

Anticipated

Primary completion date

Jun 30, 2021

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Individuals over 18 years of age who have confirmed COVID-19 infection (according to local hospital or provincial laboratories clinically approved laboratory testing for COVID-19).

Exclusion Criteria:

  • None

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Arms

COVID-19 Patients on ARBs

This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin Receptor Blockers will be included in this cohort.

COVID-19 Patients on ACE inhibitors

This is an observational cohort study. Those who have COVID-19 in hospital and are on Angiotensin-Converting Enzyme inhibitors will be included in this cohort.

COVID-19 Patients on ARBs or ACE inhibitors

This is an observational cohort study. Those who have COVID-19 in hospital and are on ARBs or ACEi's will be included in this cohort.

COVID-19 Patients not on ARBs or ACE inhibitors

This is an observational cohort study. Those who have COVID-19 in hospital and are not on ARBs or ACEi's will be included in this cohort.

Interventions

ARBs and/or ACE inhibitors

This is an observational study only.

Usual Care

This is an observational study only.

Primary outcome measure

  • COVID-19 WHO ordinal scale [ Time Frame: 14 days ]

Central Contacts and Locations

Central contacts

Puneet Mann, MSc

604 682 2344pmann7@providencehealth.bc.ca

Lynda Lazosky

604-682-2344llazosky@providencehealth.bc.ca

Locations

University of Calgary - Foothills

Recruiting

Calgary, Alberta, Canada

Stollery Children's Hospital

Recruiting

Edmonton, Alberta, Canada

University of Alberta

Recruiting

Edmonton, Alberta, Canada

St Pauls Hospital

Recruiting

Vancouver, British Columbia, Canada, V6Z1Y6

Contacts

Puneet Mann, MSc

604 682 2344pmann7@providencehealth.bc.ca

Principal Investigator:

James A Russell, MD

Vancouver General Hospital

Recruiting

Vancouver, British Columbia, Canada

William Osler Health System

Recruiting

Brampton, Ontario, Canada

Queens University

Recruiting

Kingston, Ontario, Canada

Humber River Hospital

Recruiting

North York, Ontario, Canada

Mount Sinai Hospital

Recruiting

Toronto, Ontario, Canada

Jewish General Hospital

Recruiting

Montréal, Quebec, Canada

McGill University Health Center

Recruiting

Montréal, Quebec, Canada

Université de Sherbrooke

Recruiting

Sherbrooke, Quebec, Canada

More Information

Sponsor

University of British Columbia

Last update posted

Aug 12, 2020

Last verified

Aug, 2020

Keywords

  • ARBs
  • angiotensin II type 1 receptor blocker
  • ACEi
  • acute respiratory distress syndrome
  • COVID-19
  • coronavirus
  • Multisite
  • Canada
  • Observational
  • acute kidney injury
  • shock

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of British Columbia on 2020-08-12.